SUTTER SANTA ROSA REGIONAL HOSPITAL
- Type
- Teaching hospital
- Where
- SANTA ROSA, CA
- Medicare CCN
- 050291
- Received
- $197,937 in 51 records, 2019 ($22,711 general, $175,225 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 16 | $22,711 |
| 2019 | Research payment | 35 | $175,225 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| ABBVIE INC. | 19 | $113,291 | 2019 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $54,378 | 2019 |
| Zimmer Biomet Holdings, Inc. | 6 | $9,697 | 2019 |
| GENZYME CORPORATION | 3 | $7,063 | 2019 |
| Celgene Corporation | 2 | $5,600 | 2019 |
| SANOFI-AVENTIS U.S. LLC | 2 | $4,500 | 2019 |
| Janssen Pharmaceuticals, Inc | 1 | $1,500 | 2019 |
| Allergan, Inc. | 1 | $1,392 | 2019 |
| PENTAX of America, Inc. | 1 | $248 | 2019 |
| Siemens Medical Solutions USA, Inc. | 1 | $199 | 2019 |
| Olympus America Inc. | 3 | $66 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 35 | $175,225 |
| Space rental or facility fees (teaching hospital only) | 5 | $12,500 |
| Gift | 10 | $10,012 |
| Charitable Contribution | 1 | $199 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $3,584 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $2,308 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $2,100 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $1,659 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | PENTAX of America, Inc. | $248 | Gift (2 payments) | In-kind items and services | Device, Gastroenterology | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $199 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $43 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $0 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-19 | ABBVIE INC. | $9,167 | Research payment | Cash or cash equivalent | M18-918 | 2019 | |
| 2019-12-05 | ABBVIE INC. | $2,880 | Research payment | Cash or cash equivalent | M14-397 | 2019 | |
| 2019-11-21 | ABBVIE INC. | $7,217 | Research payment | Cash or cash equivalent | M18-918 | 2019 | |
| 2019-11-20 | ABBVIE INC. | $540 | Research payment | Cash or cash equivalent | M14-222 | 2019 | |
| 2019-11-02 | GENZYME CORPORATION | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LIBTAYO Drug, ONCOLOGY | 2019 | |
| 2019-11-02 | GENZYME CORPORATION | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELITEK Drug, ONCOLOGY | 2019 | |
| 2019-10-30 | ABBVIE INC. | $1,293 | Research payment | Cash or cash equivalent | M14-222 | 2019 | |
| 2019-10-21 | ABBVIE INC. | $34,877 | Research payment | Cash or cash equivalent | M18-918 | 2019 | |
| 2019-10-12 | SANOFI-AVENTIS U.S. LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PRALUENT Drug, CARDIOVASCULAR | 2019 | |
| 2019-10-01 | ABBVIE INC. | $6,940 | Research payment | Cash or cash equivalent | M18-918 | 2019 | |
| 2019-09-23 | ABBVIE INC. | $18,874 | Research payment | Cash or cash equivalent | M18-918 | 2019 | |
| 2019-09-16 | ABBVIE INC. | $7,500 | Research payment | Cash or cash equivalent | M18-918 | 2019 | |
| 2019-09-16 | Takeda Pharmaceuticals U.S.A., Inc. | $3,747 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-08-21 | ABBVIE INC. | $3,721 | Research payment | Cash or cash equivalent | M18-918 | 2019 | |
| 2019-08-05 | Takeda Pharmaceuticals U.S.A., Inc. | $14,988 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-08-05 | Takeda Pharmaceuticals U.S.A., Inc. | $3,747 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-08-05 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-07-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,585 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-07-11 | ABBVIE INC. | $540 | Research payment | Cash or cash equivalent | M14-222 | 2019 | |
| 2019-07-11 | ABBVIE INC. | $448 | Research payment | Cash or cash equivalent | M14-222 | 2019 | |
| 2019-06-27 | ABBVIE INC. | $325 | Research payment | Cash or cash equivalent | Creon Drug, Endocrinology | P12-792 | 2019 |
| 2019-06-17 | Takeda Pharmaceuticals U.S.A., Inc. | $5,089 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-06-17 | Takeda Pharmaceuticals U.S.A., Inc. | $3,119 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-05-23 | ABBVIE INC. | $302 | Research payment | Cash or cash equivalent | M14-222 | 2019 | |
| 2019-04-26 | SANOFI-AVENTIS U.S. LLC | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PRALUENT Drug, CARDIOVASCULAR | 2019 | |
| 2019-04-22 | Takeda Pharmaceuticals U.S.A., Inc. | $14,988 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-04-22 | Takeda Pharmaceuticals U.S.A., Inc. | $243 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-04-18 | Celgene Corporation | $2,225 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Celgene - Connect MDSAML | 2019 |
| 2019-04-15 | GENZYME CORPORATION | $563 | Research payment | Cash or cash equivalent | LEMTRADA Drug, MULTIPLE SCLEROSIS | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2019 |
| 2019-03-23 | Olympus America Inc. | $36 | Gift | In-kind items and services | Device, GI & Respiratory Products | 2019 | |
| 2019-03-23 | Olympus America Inc. | $17 | Gift | In-kind items and services | 2019 | ||
| 2019-03-23 | Olympus America Inc. | $11 | Gift | In-kind items and services | Olympus Capital Accessories Device, ENT Products | 2019 | |
| 2019-03-18 | Takeda Pharmaceuticals U.S.A., Inc. | $1,802 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-03-08 | ABBVIE INC. | $3,449 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-03-07 | ABBVIE INC. | $2,940 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-02-28 | ABBVIE INC. | $6,544 | Research payment | Cash or cash equivalent | M14-222 | 2019 | |
| 2019-02-22 | Celgene Corporation | $3,375 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Celgene - Connect MDSAML | 2019 |
| 2019-02-14 | ABBVIE INC. | $4,420 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-02-14 | Allergan, Inc. | $1,392 | Research payment | Cash or cash equivalent | ZENPEP Drug, CYSTIC FIBROSIS | LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR | 2019 |
| 2019-02-14 | ABBVIE INC. | $1,308 | Research payment | Cash or cash equivalent | Creon Drug, Endocrinology | P12-792 | 2019 |
| 2019-02-11 | Takeda Pharmaceuticals U.S.A., Inc. | $1,240 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 | |
| 2019-02-05 | Janssen Pharmaceuticals, Inc | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-01-14 | Takeda Pharmaceuticals U.S.A., Inc. | $1,827 | Research payment | Cash or cash equivalent | A phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Santa Rosa, CA, county Sonoma County, CA, state California; placed by its city name.
| Measure | Place (city or town) Santa Rosa, CA | County Sonoma County, CA | State California |
|---|---|---|---|
| Population B01003 | 177,090 | 485,040 | 39,287,377 |
| Population, 2020 census P1 | 178,127 | 488,863 | 39,538,223 |
| Median age B01002 | 41.2 | 42.9 | 37.9 |
| Under 18 B01001 | 20.1% | 19.0% | 22.0% |
| 65 and over B01001 | 19.0% | 21.5% | 15.7% |
| Households B11001 | 68,321 | 190,998 | 13,548,091 |
| Foreign born B05002 | 21.2% | 16.8% | 27.0% |
| Median household income B19013 | $99,060 | $104,674 | $99,122 |
| Median family income B19113 | $120,944 | $126,900 | $113,346 |
| Per capita income B19301 | $52,066 | $56,640 | $49,513 |
| Poverty rate B17001 | 9.7% | 8.9% | 12.0% |
| Unemployment rate B23025 | 6.3% | 5.7% | 6.6% |
| Civilian labor force B23025 | 96,710 | 258,155 | 20,068,466 |
| Mean commute (minutes) B08013 | 22.9 | 25.1 | 28.7 |
| Bachelor's degree or higher B15003 | 35.1% | 38.5% | 37.1% |
| Housing units B25001 | 71,382 | 207,699 | 14,644,735 |
| Owner-occupied B25003 | 56.7% | 62.6% | 55.9% |
| Renters B25003 | 43.3% | 37.4% | 44.1% |
| Median home value B25077 | $713,900 | $815,500 | $734,700 |
| Median gross rent B25064 | $2,152 | $2,158 | $2,036 |
| White, not Hispanic B03002 | 48.7% | 57.9% | 33.8% |
| Black B03002 | 1.9% | 1.5% | 5.2% |
| Hispanic or Latino B03002 | 37.4% | 30.0% | 40.2% |
| Asian B03002 | 6.3% | 4.3% | 15.3% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Santa Rosa, CA.
Comments